Clinical Trial Information

Mitsubishi Tanabe Pharma Corporation (herein after MTPC) is working to increase transparency in clinical trial information. For details, please click here to access our Clinical Trial Information Disclosure Policy.

This website provides information related to summaries of clinical trial information, clinical trial summary results, clinical trial data to be shared with researchers, publication, and clinical trial data to be shared with patients.

Terms of Use

The information on this web page is not intended to promote or advertise MTPC products, or to recommend off-label or unapproved use of any product.

MTPC will endeavor to update information regularly on all clinical trials listed here. However, please understand that changes in clinical trial results may not always be reflected immediately in the list of summaries of clinical trial information provided on this web page.

Please note: Each individual patient is unique, and information from a specific clinical trial may be more clinically significant for some patients than for others. This clinical significance should be determined by doctors experienced in treating the specific disease that was targeted in the trial, or by other qualified healthcare professionals. If you are a patient or family member and you have any questions about the relevance of clinical trial results to your specific symptoms, please consult your doctor or other appropriate healthcare professional.

1. Registration of Clinical Trial Information and Disclosure of Results

a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries

MTPC will register and disclose information on publicly-accessible clinical trial registries such as ClinicalTrials.gov, JapicCTI, EU Clinical Trials Register regarding clinical trials that are being conducted or have been conducted. These three registries can be viewed through the links

below:

b. Disclosure of clinical trial summary results

MTPC will disclose summaries of clinical study reports outlining trials conducted in patients, and will also provide simplified summary results that can be easily understood by patients and other non-specialists.

MTPC will disclose the results from clinical trials in patients that form part of the submission package for products initially approved in the United States, Europe, or Japan (in all areas where MTPC intends to obtain marketing approval) in or after January 2018. Results will not be disclosed if MTPC decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:

  • A third party, such as a company involved in joint development, has not agreed to disclosure.
  • Disclosure may interfere with publication in medical journals.
  • Disclosure may interfere with the protection of intellectual property rights.

Summary results in plain language are currently under preparation.

c. List of summaries of clinical trial information

Summary of clinical trial information disclosed on ClinicalTrials.gov, and summary results for each clinical trial are provided in the list of summaries of clinical trial information below.
The list does not contain clinical trial information on JapicCTI which is written in Japanese.

Development code
(Generic name)
Study No. Study Title Indication Information on ClinicalTrials.gov Summary results Summary results in plain language
ClinicalTrials.gov Study Status
MT-1186
(Edaravone)
MT-1186-A03 Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) ALS NCT04577404(Registration Oct 2020) Not yet recruiting
MT-1186
(Edaravone)
MT-1186-A02 Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS ALS NCT04569084(Registration Sep 2020) Not yet recruiting
MT-7117
(Dersimelagon)
MT-7117-G02 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis Diffuse Cutaneous Systemic Sclerosis NCT04440592(Update Aug 2020) Not yet recruiting
MT-7117
(Dersimelagon)
MT-7117-G01 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria EPP, XLP NCT04402489 (Update Sep 2020) Recruiting
MT-1186
(Edaravone)
MT-1186-J05 Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy Japanese Patients With ALS NCT04254913 (Update Oct 2020) Completed
MP-513
(Teneligliptin)
3000-A4 Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes Type 2 Diabetes NCT00628212 (Update May 2013) Completed
MP-513
(Teneligliptin)
3000-A5 Monotherapy Study of MP-513 in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT00998881 (Update Feb 2014) Completed
MP-513
(Teneligliptin)
3000-A6 Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT00974090 (Update May 2014) Completed
MP-513
(Teneligliptin)
3000-A7 Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT01026194 (Update Jan 2014) Completed
MP-513
(Teneligliptin)
3000-A8 Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients Type 2 Diabetes Mellitus NCT02314637 (Update Aug 2015) Completed
MP-513
(Teneligliptin)
3000-A12 Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus NCT01072331 (Update Apr 2013) Completed
MP-513
(Teneligliptin)
3000-A14 Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT01301833 (Update Nov 2015) Completed
MP-513
(Teneligliptin)
3000-A15 Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT02081599 (Update Sep 2017) Completed
MP-513
(Teneligliptin)
MP-513-C02 Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus NCT02916706 (Update Nov 2018) Completed
MP-513
(Teneligliptin)
MP-513-C03 Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus NCT02924064 (Update Nov 2018) Completed
MP-513
(Teneligliptin)
MP-513-E07 Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT00971243 (Update Sep 2014) Completed
GMK-527
(Alteplase〔genetical recombination〕)
527-0611 Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Japan Alteplase Clinical Trial II:J-ACT II) Stroke NCT00412867 (Update Jan 2018) Completed
MP-214
(Cariprazine)
A002-A3 Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia Schizophrenia NCT00862992 (Update Sep 2009) Completed
MP-214
(Cariprazine)
A002-A4 Safety and Efficacy of MP-214 in Patients With Schizophrenia Schizophrenia NCT01625000 (Update Sep 2016) Completed
MP-214
(Cariprazine)
A002-A5 Long-Term Study of MP-214 in Patients With Schizophrenia Schizophrenia NCT01626872 (Update Apr 2017) Completed
MP-214
(Cariprazine)
A002-A7 A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia Schizophrenia NCT01625897 (Update Apr 2015) Completed
MP-214
(Cariprazine)
A002-A8 A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia Schizophrenia NCT01626885 (Update Jan 2015) Completed
MP-214
(Cariprazine)
A002-A11 A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia Schizophrenia NCT01626859 (Update Jun 2014) Completed
MCI-9038
(Argatroban)
ARG-E07 Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II Heparin-induced Thrombocytopenia Type II NCT00861692 (Update Aug 2016) Completed
BK1310 BK1310-J01 Phase 3 Study of BK1310 in Healthy Infants Immunization; Infection NCT02992925 (Update Feb 2019) Completed
BK1310 BK1310-J02 Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants Immunization NCT03188692 (Update Feb 2019) Completed
BK1310 BK1310-J03 Confirmatory Study of BK1310 in Healthy Infants Tetanus|Diphtheria|Pertussis|Poliomyelitis|Bacterial Meningitis NCT03891758 (Update May 2020) Active, not recruiting
BK1301 BKD1A Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents Diphtheria|Tetanus|Pertussis NCT02118961 (Update Jan 2017) Completed
FTY720
(Fingolimod hydrochloride)
CFTY720D1201 Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS) Multiple Sclerosis NCT00537082 (Update Apr 2011) Completed
FTY720
(Fingolimod hydrochloride)
CFTY720D1201E1 An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis Multiple Sclerosis NCT00670449 (Update Sep 2013) Completed
MP-424
(Telaprevir)
G060-A3 Safety and PK Study of MP-424 to Treat Chronic Hepatitis C Chronic Hepatitis C NCT00591214 (Update May 2014) Completed
MP-424
(Telaprevir)
G060-A5 A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C Hepatitis C NCT00630058 (Update May 2014) Completed
MP-424
(Telaprevir)
G060-A6 Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naive Patients With Chronic Hepatitis C Hepatitis C NCT00780416 (Update May 2014) Completed
MP-424
(Telaprevir)
G060-A7 Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C Hepatitis C NCT00621296 (Update May 2014) Completed
MP-424
(Telaprevir)
G060-A8 Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy Chronic Hepatitis C NCT00780910 (Update May 2014) Completed
MP-424
(Telaprevir)
G060-A9 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy Hepatitis C NCT00781274 (Update May 2014) Completed
MP-424
(Telaprevir)
G060-A10 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients Chronic Hepatitis C NCT01466192 (Update Nov 2014) Completed
MP-424
(Telaprevir)
G060-A11 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients Chronic Hepatitis C NCT01468584 (Update Nov 2014) Completed
MP-424
(Telaprevir)
G060-A12 Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naive or Relapsed Hepatitis C Chronic Hepatitis C (CHC) NCT01753557 (Update Oct 2016) Completed
MP-424
(Telaprevir)
G060-F1 Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naive or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) Chronic Hepatitis C(CHC) NCT01753570 (Update Oct 2018) Completed
MP-424
(Telaprevir)
MP-424-K01 Clinical Pharmacology Study of MP-424 Chronic Hepatitis C NCT01766167 (Update Jan 2017) Completed
MP-146 KRM-306 A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) Chronic Kidney Disease NCT00500682 (Update Mar 2015) Completed
MP-146 KRM-307 A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2) Chronic Kidney Disease NCT00501046 (Update Mar 2015) Completed
MCC-257 MCC-257-A03 Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy Diabetic Polyneuropathy NCT00307749 (Update Dec 2007) Completed
MCI-186
(Edaravone)
MCI186-13 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke Cerebral Infarction NCT00200356 (Update Jan 2013) Completed
MCI-186
(Edaravone)
MCI186-16 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis (ALS) NCT00330681 (Update May 2017) Completed
MCI-186
(Edaravone)
MCI186-17 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis (ALS) NCT00424463 (Update Aug 2018) Completed
MCI-186
(Edaravone)
MCI186-18 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III Amyotrophic Lateral Sclerosis (ALS) NCT00415519 (Update Dec 2017) Completed
MCI-186
(Edaravone)
MCI186-19 Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS) NCT01492686 (Update Dec 2018) Completed
MCI-186
(Edaravone)
MCI-186-J20 Dose Finding Study of MCI-186 in Acute Ischemic Stroke Acute Ischemic Stroke NCT03346538 (Update Sep 2018) Terminated
MCI-186
(Edaravone)
MCI-186-E04 Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke Acute Ischemic Stroke (AIS) NCT00821821 (Update May 2014) Completed
MT-1186
(Edaravone)
MT-1186-A01 Safety Study of Oral Edaravone Administered in Subjects With ALS ALS NCT04165824 (Update Oct 2020) Active, not recruiting
MT-1186
(Edaravone)
MT-1186-J04 Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis Japanese Patients With ALS NCT04176224 (Registration  Nov 2019) Completed
MCI-196
(Colestimide/
Colestilan)
MCI196-19 Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes Type 2 Diabetes NCT00497198 (Update Jun 2012) Completed
MCI-196
(Colestimide/
Colestilan)
MCI-196-A05 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Chronic Kidney Disease|Dialysis|Hyperphosphatemia NCT00506441 (Update Sep 2014) Completed
MCI-196
(Colestimide/
Colestilan)
MCI-196-A06 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Chronic Kidney Disease|Dialysis|Hyperphosphatemia NCT00772382 (Update Sep 2014) Completed
MCI-196
(Colestimide/
Colestilan)
MCI-196-E07 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Chronic Kidney Disease|Hyperphosphatemia NCT00416520 (Update Nov 2014) Completed
MCI-196
(Colestimide/
Colestilan)
MCI-196-E08 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Dyslipidemia NCT00542386 (Update Oct 2014) Completed
MCI-196
(Colestimide/
Colestilan)
MCI-196-E09 A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia Chronic Kidney Disease|Dialysis|Hyperphosphatemia NCT00451295 (Update Nov 2011) Terminated
MCI-196
(Colestimide/
Colestilan)
MCI-196-E10 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Chronic Kidney Disease|Dialysis|Hyperphosphatemia NCT00542815 (Update Oct 2014) Completed
MCI-196
(Colestimide/
Colestilan)
MCI-196-E11 Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis Chronic Kidney Disease NCT00858637 (Update Dec 2014) Completed
MCI-196
(Colestimide/
Colestilan)
MCI-196-E14 Dose-finding Study of MCI-196 Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Paediatric NCT01814904 (Update May 2015) Terminated
MCI-196
(Colestimide/
Colestilan)
MCI-196-E15 Long-term Extension Study of MCI-196 Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Paediatric NCT01814917 (Update May 2015) Terminated
MCI-196
(Colestimide/
Colestilan)
MCI-196-E16 Safety and Tolerability Study of MCI-196 Chronic Kidney Disease|Not on Dialysis|Hyperphosphatemia|Paediatric NCT01818687 (Update May 2015) Terminated
MCI-9042
(Sarpogrelate)
MCI9042-15 Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS) Cerebral Infarction NCT00129805 (Update Aug 2008) Completed
MCI-9042
(Sarpogrelate)
MCI9042-17 Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study Cerebral Infarction NCT00147303 (Update Apr 2015) Completed
MP-435 MP-435-J04 Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis Rheumatoid Arthritis NCT01143337 (Update Oct 2014) Completed
MT-1303
(Amiselimod)
MT-1303-E03 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease Inflammatory Bowel Disease NCT01666327 (Update Sep 2014) Completed
MT-1303
(Amiselimod)
MT-1303-E04 Dose-finding Study of MT-1303 Relapsing-remitting Multiple Sclerosis NCT01742052 (Update Sep 2016) Completed
MT-1303
(Amiselimod)
MT-1303-E05 Extension Study of MT-1303 Relapsing-remitting Multiple Sclerosis NCT01890655 (Update Apr 2016) Completed
MT-1303
(Amiselimod)
MT-1303-E06 Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Plaque Psoriasis NCT01987843 (Update Dec 2014) Completed
MT-1303
(Amiselimod)
MT-1303-E13 Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease Crohn's Disease NCT02378688 (Update Oct 2016) Completed
MT-1303
(Amiselimod)
MT-1303-E14 Extension Study of MT-1303 in Subjects With Crohn's Disease Crohn's Disease NCT02389790 (Update Sep 2017) Completed
MT-1303
(Amiselimod)
MT-1303-J02 Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease Crohn's Disease NCT02148185 (Update Sep 2014) Completed
MT-1303
(Amiselimod)
MT-1303-J03 Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients Systemic Lupus Erythematosus NCT02307643 (Update Jun 2017) Completed
MT-2301 MT-2301-J01 Exploratory Clinical Study of MT-2301 Haemophilus Influenza Type b NCT02140047 (Update Oct 2015) Completed
MT-2412
(Teneligliptin,Canagliflozin)
MT-2412-J01 Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT02220907 (Update Nov 2018) Completed
MT-2412
(Teneligliptin,Canagliflozin)
MT-2412-J02 Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) Type 2 Diabetes Mellitus NCT02354222 (Update Nov 2018) Completed
MT-2412
(Teneligliptin,Canagliflozin)
MT-2412-J03 Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) Type 2 Diabetes Mellitus NCT02354235 (Update Nov 2018) Completed
MT-2990 MT-2990-A01 Safety and Efficacy Study of MT-2990 in Women With Endometriosis Endometrial Related Pain NCT03840993 (Update Sep 2020) Recruiting
MT-2990 MT-2990-J01 A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients Seasonal Allergic Rhinitis NCT03570957 (Update Jan 2019) Completed
MT-3921 MT-3921-G01 Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury Spinal Cord Injury NCT04096950 (Update Aug 2020) Recruiting
MT-3995
(Apararenone)
MT-3995-E06 A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria Diabetic Nephropathy NCT01756703 (Update Feb 2015) Completed
MT-3995
(Apararenone)
MT-3995-E07 A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR Diabetic Nephropathy NCT01756716 (Update Feb 2015) Completed
MT-3995
(Apararenone)
MT-3995-J03 Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy Diabetic Nephropathy NCT01889277 (Update Jan 2015) Completed
MT-3995
(Apararenone)
MT-3995-J04 Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy Diabetic Nephropathy NCT02205372 (Update Sep 2015) Completed
MT-3995
(Apararenone)
MT-3995-J05 Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy Diabetic Nephropathy NCT02517320 (Update Mar 2017) Completed
MT-3995
(Apararenone)
MT-3995-J06 An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy Diabetic Nephropathy NCT02676401 (Update Sep 2017) Completed
MT-3995
(Apararenone)
MT-3995-J07 Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) NASH NCT02923154 (Update Sep 2019) Completed
MT-5199
(Valbenazine)
MT-5199-J02 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Tardive Dyskinesia NCT03176771 (Update Oct 2020) Completed
MT-5547
(Fasinumab)
MT-5547-J01 Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain Osteoarthritis, Knee / Osteoarthritis, Hip NCT03245008 (Update Oct 2019) Active, not recruiting
MT-5625 MT-5625-01 Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants Healthy NCT03507738 (Update Aug 2019) Completed
MT-6548
(Vadadustat)
MT-6548-J01 Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan Anemia; Non-dialysis Dependent Chronic Kidney Disease NCT03329196 (Update Oct 2019) Completed
MT-6548
(Vadadustat)
MT-6548-J02 Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease NCT03402386 (Update Mar 2019) Completed
MT-6548
(Vadadustat)
MT-6548-J03 Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan Anemia; Hemodialysis Dependent Chronic Kidney Disease NCT03439137 (Update Oct 2019) Completed
MT-6548
(Vadadustat)
MT-6548-J04 Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan Anemia; Hemodialysis Dependent Chronic Kidney Disease NCT03461146 (Update Mar 2019) Completed
MT-7117
(Dersimelagon)
MT-7117-A01 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria Erythropoietic Protoporphyria (EPP) NCT03520036 (Update Sep 2020) Completed
MT-8554
(Elismetrep)
MT-8554-A01 MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women Menopause Hot Flashes NCT03291067 (Update Oct 2019) Completed
MT-8554
(Elismetrep)
MT-8554-A02 Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms Vasomotor Symptoms (VMS) NCT03541200 (Update Jan 2020) Completed
MT-8554
(Elismetrep)
MT-8554-E04 A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms Vasomotor Symptoms NCT02803268 (Update Feb 2017) Completed
MT-8554
(Elismetrep)
MT-8554-E06 Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy Painful Diabetic Peripheral Neuropathy NCT03172598 (Update Aug 2018) Completed
TA-650
(Infliximab
[recombinant])
TA-650-13 Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis Rheumatoid Arthritis NCT00691028 (Update Mar 2014) Completed
TA-650
(Infliximab
[recombinant])
TA-650-19 Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD) Crohn's Disease NCT00805766 (Update Feb 2018) Completed
TA-650
(Infliximab
[recombinant])
TA-650-20 Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease Pediatric Crohn's Disease NCT01580670 (Update Jul 2019) Completed
TA-650
(Infliximab
[recombinant])
TA-650-21 Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis Pediatric Ulcerative Colitis NCT01585155 (Update Nov 2019) Completed
TA-650
(Infliximab
[recombinant])
TA-650-22 Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin NCT01596335 (Update Oct 2018) Completed
TA-650
(Infliximab
[recombinant])
TA-650-23 Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions Behcet's Disease|Behcet Syndrome|Neuro-Behcet's Disease NCT01532570 (Update Dec 2016) Completed
TA-650
(Infliximab
[recombinant])
TA-650-24 A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis Plaque Psoriasis|Psoriatic Arthritis|Pustular Psoriasis (Excluding a Localized)|Psoriatic Erythroderma NCT01680159 (Update Mar 2017) Completed
TA-7284
(Canagliflozin)
TA-7284-02 Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients Type 2 Diabetes Mellitus NCT00707954 (Update Apr 2014) Completed
TA-7284
(Canagliflozin)
TA-7284-04 An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT01022112 (Update Jun 2014) Completed
TA-7284
(Canagliflozin)
TA-7284-05 Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes Type 2 Diabetes Mellitus NCT01413204 (Update Jun 2014) Completed
TA-7284
(Canagliflozin)
TA-7284-06 Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus NCT01387737 (Update Jun 2014) Completed
TA-7284
(Canagliflozin)
TA-7284-07 A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment Type 2 Diabetes Mellitus NCT01512849 (Update Jun 2014) Completed
TA-7284
(Canagliflozin)
TA-7284-11 Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus NCT02220920 (Update Dec 2016) Completed
TA-7284
(Canagliflozin)
TA-7284-12 Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus NCT02227849 (Update Apr 2019) Completed
TA-7284
(Canagliflozin)
TA-7284-13 Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus NCT02622113 (Update Apr 2019) Completed
TA-7284
(Canagliflozin)
TA-7284-14 Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy Diabetic Nephropathy NCT03436693 (Update Apr 2020) Active, not recruiting
TAU-284
(Bepotastine)
TAU-284-17 A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis Perennial Allergic Rhinitis NCT01425632 (Update Dec 2015) Completed
TAU-284
(Bepotastine)
TAU-284-18 A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis Perennial Allergic Rhinitis NCT01900054 (Update Apr 2016) Completed
TAU-284
(Bepotastine)
TAU-284-19 A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis Dermatitis|Atopic NCT01840605 (Update May 2018) Completed
TAU-284
(Bepotastine)
TAU-284-20 The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis Perennial Allergic Rhinitis NCT01861522 (Update Dec 2015) Completed

2. Sharing Clinical Trial Data with Researchers

When requested by a qualified researcher in the field of science or medicine, MTPC will share clinical trial data that was collected from individual patients in a clinical trial with that researcher after a review committee of experts determines that such sharing is appropriate. Such clinical data will always be anonymized before sharing. MTPC will not share data that MTPC feels may place the patient at risk of being identified.

MTPC will share patient data from clinical trials in patients that form part of the submission package for products initially approved in the United States, Europe, or Japan (in all areas where MTPC intends to obtain marketing approval) in or after January 2018. Please use the following link for other conditions and limitations.

https://vivli.org/ourmember/mitsubishi-tanabe-pharma/

Researchers: Please use the link below to request data sharing.

https://vivli.org/

3. Publication of Clinical Trial Results

MTPC in a timely manner, will endeavor to provide relevant presentations at scientific meetings, or publications in scientific journals, of the clinical trial results where results are considered to be of significant medical importance. When such an article is published, MTPC will cite the publication on publicly accessible clinical trial registries.

4. Sharing Clinical Trial Results with Patients Who Participate in Clinical Trials

MTPC plans to share personal patient results from clinical trials individually with each clinical trial participant. This information-sharing program is currently in the planning stages.

Questions

If you have any questions about disclosure of clinical trial information, please email us:

MTPC-CTDS-office@cc.mt.pharm.co.jp